First HER2/4-1BB Bispecific Molecule Shows Clinical Activity in HER2+ Cancers
November 11, 2019
PRS-343, a HER2/4-1BB targeting bispecific construct, is well-tolerated and demonstrated anti-tumor activity in heavily pre-treated patient population across multiple tumor types.